Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Genetic and Epigenetic of Medullary Thyroid Cancer Publisher Pubmed



Khatami F1 ; Tavangar SM1, 2
Authors

Source: Iranian Biomedical Journal Published:2018


Abstract

Medullary thyroid carcinoma (MTC) is an infrequent calcitonin-producing neuroendocrine tumor that initiates from the parafollicular C cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we shed light on all the genetic and epigenetic hallmarks of MTC. From the genetic perspective, RET, HRAS, and KRAS are the most important genes that are characterized in MTC. From the epigenetic perspective, Ras-association domain family member 1A, telomerase reverse transcriptase promoter methylations, overexpression of histone methyltransferases, EZH2 and SMYD3, and wide ranging increase and decrease in non-coding RNAs can be responsible for medullary thyroid carcinogenesis. © 2018, Pasteur Institute of Iran. All rights reserved.
Related Docs
View other Related Docs
1. Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma, Iranian Journal of Pathology (2019)
2. Multiple Endocrine Neoplasia Syndromes From Genetic and Epigenetic Perspectives, Biomarker Insights (2018)
3. A Review of Driver Genetic Alterations in Thyroid Cancers, Iranian Journal of Pathology (2018)
Experts (# of related papers)
View all Related Experts
Seyed Mohammad Tavangar (17)
Bagher Larijani (9)
Other Related Docs
4. Multiple Endocrine Neoplasia Syndromes From Genetic and Epigenetic Perspectives, Biomarker Insights (2018)
5. Circulating Ctdna Methylation Quantification of Two Dna Methyl Transferases in Papillary Thyroid Carcinoma, Journal of Cellular Biochemistry (2019)
6. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)
7. Genetic and Epigenetic Differences of Benign and Malignant Pheochromocytomas and Paragangliomas (Ppgls), Endocrine Regulations (2018)
8. Liquid Biopsy As a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations, International Journal of Molecular and Cellular Medicine (2019)
9. Thyroid Cancer Research at Endocrinology and Metabolism Research Institute (Emri): A Report of Scientific Activities Between 2005 and 2020, Journal of Diabetes and Metabolic Disorders (2021)
10. The Role of Micrornas in Different Types of Thyroid Carcinoma: A Comprehensive Analysis to Find New Mirna Supplementary Therapies, Journal of Endocrinological Investigation (2018)
11. Hypermethylated Rassf1 and Slc5a8 Promoters Alongside Brafv600e Mutation As Biomarkers for Papillary Thyroid Carcinoma, Journal of Cellular Physiology (2020)
12. Personalized Treatment Options for Thyroid Cancer: Current Perspectives, Pharmacogenomics and Personalized Medicine (2019)
13. Meta-Analysis of Promoter Methylation in Eight Tumor-Suppressor Genes and Its Association With the Risk of Thyroid Cancer, PLoS ONE (2017)
14. Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review, Iranian Journal of Pathology (2017)
15. Germline Mutations of Ret Proto-Oncogene Exon 2 in Iranian Population With Medullary Thyroid Carcinoma, Koomesh (2016)
16. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
17. Evaluation of Mirnas Expression in Medullary Thyroid Carcinoma Tissue Samples: Mir-34A and Mir-144 As Promising Overexpressed Markers in Mtc, Human Pathology (2018)
18. Oncometabolites As Biomarkers in Thyroid Cancer: A Systematic Review, Cancer Management and Research (2019)
19. Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation, Iranian Journal of Public Health (2022)
20. The Presence of Tumor Extrachomosomal Circular Dna (Ecdna) As a Component of Liquid Biopsy in Blood, Medical Hypotheses (2018)